Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis

One year of adjuvant trastuzumab is considered the standard treatment for patients with HER2 positive breast cancer. However, a shorter duration of trastuzumab may be associated with reduced costs and side effects. Results from randomized trials with diverse non-inferiority margins comparing one yea...

Descripción completa

Detalles Bibliográficos
Autores principales: Stewart, Paul, Blanchette, Phillip, Shah, Prakesh S., Ye, Xiang Y., Boldt, R. Gabriel, Fernandes, Ricardo, Vandenberg, Ted, Raphael, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599130/
https://www.ncbi.nlm.nih.gov/pubmed/33130486
http://dx.doi.org/10.1016/j.breast.2020.10.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599130/
https://www.ncbi.nlm.nih.gov/pubmed/33130486
http://dx.doi.org/10.1016/j.breast.2020.10.003

Ejemplares similares